Intratumoral chemotherapy for lung cancer

Re-challenge current targeted therapies

Wolfgang Hohenforst-Schmidt, Paul Zarogoulidis, Kaid Darwiche, Thomas Vogl, Eugene P. Goldberg, Haidong Huang, Michael Simoff, Qiang Li, Robert Browning, J. Turner, Patrick Le Pivert, Dionysios Spyratos, Konstantinos Zarogoulidis, Seyhan I. Celikoglu, Firuz Celikoglu, Johannes Brachmann

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Strategies to enhance the already established doublet chemotherapy regimen for lung cancer have been investigated for more than 20 years. Initially, the concept was to administer chemotherapy drugs locally to the tumor site for efficient diffusion through passive transport within the tumor. Recent advances have enhanced the diffusion of pharmaceuticals through active transport by using pharmaceuticals designed to target the genome of tumors. In the present study, five patients with non-small cell lung cancer epidermal growth factor receptor (EGFR) negative stage IIIa-IV International Union Against Cancer 7 (UICC-7), and with Eastern Cooperative Oncology Group (ECOG) 2 scores were administered platinum-based doublet chemotherapy using combined intratumoral-regional and intravenous route of administration. Cisplatin analogues were injected at 0.5%-1% concentration within the tumor lesion and proven malignant lymph nodes according to pretreatment histological/cytological results and the concentration of systemic infusion was decreased to 70% of a standard protocol. This combined intravenous plus intratumoral-regional chemotherapy is used as a first line therapy on this short series of patients. To the best of our knowledge this is the first report of direct treatment of involved lymph nodes with cisplatin by endobronchial ultrasound drug delivery with a needle without any adverse effects. The initial overall survival and local response are suggestive of a better efficacy compared to established doublet cisplatin-based systemic chemotherapy in (higher) standard concentrations alone according to the UICC 7 database expected survival. An extensive search of the literature was performed to gather information of previously published literature of intratumoral chemo-drug administration and formulation for this treatment modality. Our study shows a favorable local response, more than a 50% reduction, for a massive tumor mass after administration of five sessions of intratumoral chemotherapy plus two cycles of low-dose intravenous chemotherapy according to our protocol. These encouraging results (even in very sick ECOG 2 patients with central obstructive non-small cell lung cancer having a worse prognosis and quality of life than a non-small cell lung cancer in ECOG 0 of the same tumor node metastasis [TNM]-stage without central obstruction) for a chemotherapy-only protocol that differs from conventional cisplatin-based doublet chemotherapy by the route, target site, and dose paves the way for broader applications of this technique. Finally, future perspectives of this treatment and pharmaceutical design for intratumoral administration are presented.

Original languageEnglish (US)
Pages (from-to)571-583
Number of pages13
JournalDrug Design, Development and Therapy
Volume7
DOIs
StatePublished - Jul 26 2013

Fingerprint

Lung Neoplasms
Drug Therapy
Cisplatin
Non-Small Cell Lung Carcinoma
Neoplasms
Pharmaceutical Preparations
Therapeutics
Lymph Nodes
Drug Compounding
Survival
Active Biological Transport
Platinum
Epidermal Growth Factor Receptor
Intravenous Administration
Needles
Quality of Life
Genome
Databases
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Hohenforst-Schmidt, W., Zarogoulidis, P., Darwiche, K., Vogl, T., Goldberg, E. P., Huang, H., ... Brachmann, J. (2013). Intratumoral chemotherapy for lung cancer: Re-challenge current targeted therapies. Drug Design, Development and Therapy, 7, 571-583. https://doi.org/10.2147/DDDT.S46393

Intratumoral chemotherapy for lung cancer : Re-challenge current targeted therapies. / Hohenforst-Schmidt, Wolfgang; Zarogoulidis, Paul; Darwiche, Kaid; Vogl, Thomas; Goldberg, Eugene P.; Huang, Haidong; Simoff, Michael; Li, Qiang; Browning, Robert; Turner, J.; Le Pivert, Patrick; Spyratos, Dionysios; Zarogoulidis, Konstantinos; Celikoglu, Seyhan I.; Celikoglu, Firuz; Brachmann, Johannes.

In: Drug Design, Development and Therapy, Vol. 7, 26.07.2013, p. 571-583.

Research output: Contribution to journalArticle

Hohenforst-Schmidt, W, Zarogoulidis, P, Darwiche, K, Vogl, T, Goldberg, EP, Huang, H, Simoff, M, Li, Q, Browning, R, Turner, J, Le Pivert, P, Spyratos, D, Zarogoulidis, K, Celikoglu, SI, Celikoglu, F & Brachmann, J 2013, 'Intratumoral chemotherapy for lung cancer: Re-challenge current targeted therapies', Drug Design, Development and Therapy, vol. 7, pp. 571-583. https://doi.org/10.2147/DDDT.S46393
Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, Vogl T, Goldberg EP, Huang H et al. Intratumoral chemotherapy for lung cancer: Re-challenge current targeted therapies. Drug Design, Development and Therapy. 2013 Jul 26;7:571-583. https://doi.org/10.2147/DDDT.S46393
Hohenforst-Schmidt, Wolfgang ; Zarogoulidis, Paul ; Darwiche, Kaid ; Vogl, Thomas ; Goldberg, Eugene P. ; Huang, Haidong ; Simoff, Michael ; Li, Qiang ; Browning, Robert ; Turner, J. ; Le Pivert, Patrick ; Spyratos, Dionysios ; Zarogoulidis, Konstantinos ; Celikoglu, Seyhan I. ; Celikoglu, Firuz ; Brachmann, Johannes. / Intratumoral chemotherapy for lung cancer : Re-challenge current targeted therapies. In: Drug Design, Development and Therapy. 2013 ; Vol. 7. pp. 571-583.
@article{3965f70ed7bd49eea3b3c1921cb9fc34,
title = "Intratumoral chemotherapy for lung cancer: Re-challenge current targeted therapies",
abstract = "Strategies to enhance the already established doublet chemotherapy regimen for lung cancer have been investigated for more than 20 years. Initially, the concept was to administer chemotherapy drugs locally to the tumor site for efficient diffusion through passive transport within the tumor. Recent advances have enhanced the diffusion of pharmaceuticals through active transport by using pharmaceuticals designed to target the genome of tumors. In the present study, five patients with non-small cell lung cancer epidermal growth factor receptor (EGFR) negative stage IIIa-IV International Union Against Cancer 7 (UICC-7), and with Eastern Cooperative Oncology Group (ECOG) 2 scores were administered platinum-based doublet chemotherapy using combined intratumoral-regional and intravenous route of administration. Cisplatin analogues were injected at 0.5{\%}-1{\%} concentration within the tumor lesion and proven malignant lymph nodes according to pretreatment histological/cytological results and the concentration of systemic infusion was decreased to 70{\%} of a standard protocol. This combined intravenous plus intratumoral-regional chemotherapy is used as a first line therapy on this short series of patients. To the best of our knowledge this is the first report of direct treatment of involved lymph nodes with cisplatin by endobronchial ultrasound drug delivery with a needle without any adverse effects. The initial overall survival and local response are suggestive of a better efficacy compared to established doublet cisplatin-based systemic chemotherapy in (higher) standard concentrations alone according to the UICC 7 database expected survival. An extensive search of the literature was performed to gather information of previously published literature of intratumoral chemo-drug administration and formulation for this treatment modality. Our study shows a favorable local response, more than a 50{\%} reduction, for a massive tumor mass after administration of five sessions of intratumoral chemotherapy plus two cycles of low-dose intravenous chemotherapy according to our protocol. These encouraging results (even in very sick ECOG 2 patients with central obstructive non-small cell lung cancer having a worse prognosis and quality of life than a non-small cell lung cancer in ECOG 0 of the same tumor node metastasis [TNM]-stage without central obstruction) for a chemotherapy-only protocol that differs from conventional cisplatin-based doublet chemotherapy by the route, target site, and dose paves the way for broader applications of this technique. Finally, future perspectives of this treatment and pharmaceutical design for intratumoral administration are presented.",
author = "Wolfgang Hohenforst-Schmidt and Paul Zarogoulidis and Kaid Darwiche and Thomas Vogl and Goldberg, {Eugene P.} and Haidong Huang and Michael Simoff and Qiang Li and Robert Browning and J. Turner and {Le Pivert}, Patrick and Dionysios Spyratos and Konstantinos Zarogoulidis and Celikoglu, {Seyhan I.} and Firuz Celikoglu and Johannes Brachmann",
year = "2013",
month = "7",
day = "26",
doi = "10.2147/DDDT.S46393",
language = "English (US)",
volume = "7",
pages = "571--583",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Intratumoral chemotherapy for lung cancer

T2 - Re-challenge current targeted therapies

AU - Hohenforst-Schmidt, Wolfgang

AU - Zarogoulidis, Paul

AU - Darwiche, Kaid

AU - Vogl, Thomas

AU - Goldberg, Eugene P.

AU - Huang, Haidong

AU - Simoff, Michael

AU - Li, Qiang

AU - Browning, Robert

AU - Turner, J.

AU - Le Pivert, Patrick

AU - Spyratos, Dionysios

AU - Zarogoulidis, Konstantinos

AU - Celikoglu, Seyhan I.

AU - Celikoglu, Firuz

AU - Brachmann, Johannes

PY - 2013/7/26

Y1 - 2013/7/26

N2 - Strategies to enhance the already established doublet chemotherapy regimen for lung cancer have been investigated for more than 20 years. Initially, the concept was to administer chemotherapy drugs locally to the tumor site for efficient diffusion through passive transport within the tumor. Recent advances have enhanced the diffusion of pharmaceuticals through active transport by using pharmaceuticals designed to target the genome of tumors. In the present study, five patients with non-small cell lung cancer epidermal growth factor receptor (EGFR) negative stage IIIa-IV International Union Against Cancer 7 (UICC-7), and with Eastern Cooperative Oncology Group (ECOG) 2 scores were administered platinum-based doublet chemotherapy using combined intratumoral-regional and intravenous route of administration. Cisplatin analogues were injected at 0.5%-1% concentration within the tumor lesion and proven malignant lymph nodes according to pretreatment histological/cytological results and the concentration of systemic infusion was decreased to 70% of a standard protocol. This combined intravenous plus intratumoral-regional chemotherapy is used as a first line therapy on this short series of patients. To the best of our knowledge this is the first report of direct treatment of involved lymph nodes with cisplatin by endobronchial ultrasound drug delivery with a needle without any adverse effects. The initial overall survival and local response are suggestive of a better efficacy compared to established doublet cisplatin-based systemic chemotherapy in (higher) standard concentrations alone according to the UICC 7 database expected survival. An extensive search of the literature was performed to gather information of previously published literature of intratumoral chemo-drug administration and formulation for this treatment modality. Our study shows a favorable local response, more than a 50% reduction, for a massive tumor mass after administration of five sessions of intratumoral chemotherapy plus two cycles of low-dose intravenous chemotherapy according to our protocol. These encouraging results (even in very sick ECOG 2 patients with central obstructive non-small cell lung cancer having a worse prognosis and quality of life than a non-small cell lung cancer in ECOG 0 of the same tumor node metastasis [TNM]-stage without central obstruction) for a chemotherapy-only protocol that differs from conventional cisplatin-based doublet chemotherapy by the route, target site, and dose paves the way for broader applications of this technique. Finally, future perspectives of this treatment and pharmaceutical design for intratumoral administration are presented.

AB - Strategies to enhance the already established doublet chemotherapy regimen for lung cancer have been investigated for more than 20 years. Initially, the concept was to administer chemotherapy drugs locally to the tumor site for efficient diffusion through passive transport within the tumor. Recent advances have enhanced the diffusion of pharmaceuticals through active transport by using pharmaceuticals designed to target the genome of tumors. In the present study, five patients with non-small cell lung cancer epidermal growth factor receptor (EGFR) negative stage IIIa-IV International Union Against Cancer 7 (UICC-7), and with Eastern Cooperative Oncology Group (ECOG) 2 scores were administered platinum-based doublet chemotherapy using combined intratumoral-regional and intravenous route of administration. Cisplatin analogues were injected at 0.5%-1% concentration within the tumor lesion and proven malignant lymph nodes according to pretreatment histological/cytological results and the concentration of systemic infusion was decreased to 70% of a standard protocol. This combined intravenous plus intratumoral-regional chemotherapy is used as a first line therapy on this short series of patients. To the best of our knowledge this is the first report of direct treatment of involved lymph nodes with cisplatin by endobronchial ultrasound drug delivery with a needle without any adverse effects. The initial overall survival and local response are suggestive of a better efficacy compared to established doublet cisplatin-based systemic chemotherapy in (higher) standard concentrations alone according to the UICC 7 database expected survival. An extensive search of the literature was performed to gather information of previously published literature of intratumoral chemo-drug administration and formulation for this treatment modality. Our study shows a favorable local response, more than a 50% reduction, for a massive tumor mass after administration of five sessions of intratumoral chemotherapy plus two cycles of low-dose intravenous chemotherapy according to our protocol. These encouraging results (even in very sick ECOG 2 patients with central obstructive non-small cell lung cancer having a worse prognosis and quality of life than a non-small cell lung cancer in ECOG 0 of the same tumor node metastasis [TNM]-stage without central obstruction) for a chemotherapy-only protocol that differs from conventional cisplatin-based doublet chemotherapy by the route, target site, and dose paves the way for broader applications of this technique. Finally, future perspectives of this treatment and pharmaceutical design for intratumoral administration are presented.

UR - http://www.scopus.com/inward/record.url?scp=84880436777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880436777&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S46393

DO - 10.2147/DDDT.S46393

M3 - Article

VL - 7

SP - 571

EP - 583

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -